



Sema4[®] offers an expansive portfolio of state-of-the-art genetic tests for reproductive health

Why Sema4?

Sema4 is a patient-centered predictive health company and a leader in genetic and genomic testing. The company is founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. A Mount Sinai Health System venture based in Stamford, Connecticut, Sema4 is enabling physicians and patients to more seamlessly engage the digital universe of data, from genome test results and clinical records to wearable sensor metrics and more. We currently offer advanced genome-based diagnostics for reproductive health and oncology and are building predictive models of complex disease. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

At Sema4, we utilize state-of-the-art technologies and are continuously developing new tests to support patient care. We understand the complexity that comes with navigating the world of genetics and genomics—including test ordering, billing, insurance coverage, genetic counseling, and reporting of results —and offer services and digital tools to support you, your practice, and your patients.

Learn more at sema4.com.



Clinically broad

- Wide range of high-quality reproductive health tests and services to support you and your patients from preconception to birth
- State-of-the-art technology to ensure high detection rates and accurate results
- Ongoing development of new test offerings, based on years of research and patient care



Commitment to service

- Personalized services to seamlessly align with your practice workflow
- Digital tools, such as the Sema4 provider portal, to make it easy for you to order and review test results, access detailed test information, and interface with your EMR
- Genetic counseling services for your patients and practice to offer education, assistance interpreting results, and guidance on care options




Support for patients

- In-network with the majority of national and regional insurers. We also accept both Medicaid and Medicare and are dedicated to helping providers and patients navigate the billing landscape
- Patient-friendly billing policies, including competitive self-pay prices and financial assistance programs
- Patients can track their tests, view results, and access educational materials through the Sema4 patient portal



Tests for every stage of the reproductive journey



Testing may include: Rapid FISH, Site Specific FISH, Karyotype, microarray, Whole Exome Sequencing, Whole Genome Sequencing, Molecular Testing, Biochemical Testing

Carrier screening, including Sema4 Expanded Carrier Screen for 283 genes, Comprehensive Jewish Carrier Screen, smaller panels available upon request, and enhanced testing for spinal muscular atrophy (SMA) which may detect silent carriers.

Prenatal testing, including Sema4 Noninvasive Prenatal Select which can detect chromosomal abnormalities as early as 9 weeks into pregnancy, and other noninvasive prenatal testing (NIPT).

Supplemental newborn screening - Sema4 Natalis, a newborn test that screens for 193 treatable childhood conditions and analyzes a child's response to more than 40 commonly prescribed medications.

Diagnostic sequencing and testing, including tests for Fragile X syndrome, congenital limb defects, microcephaly, Noonan syndrome, and skeletal dysplasias.

Cytogenetic and cytogenomic testing, including Products of Conception (POC) microarray, targeted and high-resolution microarrays, chromosome analysis, and fluorescence in situ hybridization (FISH).

Biochemical testing, including testing for Tay-Sachs disease, Sandhoff disease, and Fabry disease.

Sema4 Expanded Carrier Screen

Sema4 Expanded Carrier Screen (ECS) for 283 genes, powered by advanced sequencing technologies.



Expansive

Broad pan-ethnic carrier screen for 283 genes associated with severe or progressive inherited disorders to provide families with critical health information. **Prenatal diagnostic testing is available for all genes on the panel.**



Flexible

Prefer to screen for a smaller panel of genes? Sema4 can accommodate any selection of the 283 genes you would like to test, including single gene testing for partners.



Accurate

When assessing risk, precision matters. Sema4 ECS uses nine testing technologies for results that are >95% clinically accurate, regardless of ethnicity.



Simple

Results are delivered in an easy-to-interpret report. Genetic counseling is available to help support and educate patients.

The American College of Obstetricians and Gynecologists (ACOG) recommends expanded carrier screening be offered to all women who are pregnant or planning to become pregnant. "Carrier screening and counseling ideally should be performed before pregnancy because this enables couples to learn about their reproductive risk and consider the most complete range of reproductive options." (ACOG Committee Opinion, March 2017). For more information, visit <http://bit.ly/acogcarrierscreening>.

sema4.com
800-298-6470
support@sema4.com

